Literature DB >> 21592114

α-Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cells.

M Yamamoto1, T Tatsumi, T Miyagi, H Tsunematsu, H Aketa, A Hosui, T Kanto, N Hiramatsu, N Hayashi, T Takehara.   

Abstract

α-Fetoprotein (AFP) is a tumour-associated antigen in hepatocellular carcinoma (HCC). The biological properties of AFP have been identified in its regulatory effects on immune responses of T cells and B cells. However, AFP effects on natural killer (NK) cells are still unclear. In this study, we examined the immunoregulation of AFP on NK activity. The cytolytic activity against K562 cells and Huh7 cells of NK cells co-cultured with AFP-treated dendritic cells (DCs) (AFP-DCs) was lower than that with albumin-treated DCs (Alb-DCs). Direct addition of AFP to NK cells did not alter the cytolytic activity of NK cells. Adding AFP inhibited the interleukin (IL)-12 production of DCs after stimulation with lipopolysaccharide (LPS) [Toll-like receptor (TLR)-4 ligand], or Poly(I:C) (TLR-3 ligand), but not IL-18 production. The mRNAs of IL-12p35 and IL-12p40 were significantly inhibited in AFP-DCs compared with Alb-DCs, but those of TLR-4 or TLR-3 were not. Transwell experiments revealed that soluble factors derived from DCs played roles in inhibition of the ability of activating NK cells by AFP-DCs. Adding the neutralizing antibody of IL-12 to NK cells co-cultured with Alb-DCs resulted in a decrease of cytolytic activity to the levels of NK cells co-cultured with AFP-DCs. Adding IL-12 to NK cells co-cultured with AFP-DCs resulted in an increase of cytolytic activity to the levels of NK cells co-cultured with Alb-DCs. These demonstrated that the impairment of IL-12 production from AFP-DCs resulted in inhibition of the ability of the activation of NK cells by DCs, and thus suggests a role of AFP in HCC development.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21592114      PMCID: PMC3142646          DOI: 10.1111/j.1365-2249.2011.04421.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

Review 1.  Immunology of the healthy liver: old questions and new insights.

Authors:  W Z Mehal; F Azzaroli; I N Crispe
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

2.  Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.

Authors:  Cai Zhang; Jianhua Zhang; Jiafeng Niu; Zhixia Zhou; Jian Zhang; Zhigang Tian
Journal:  Hum Immunol       Date:  2008-07-09       Impact factor: 2.850

3.  Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.

Authors:  Kenichi Takayasu; Shigeki Arii; Iwao Ikai; Masao Omata; Kiwamu Okita; Takafumi Ichida; Yutaka Matsuyama; Yasuni Nakanuma; Masamichi Kojiro; Masatoshi Makuuchi; Yoshio Yamaoka
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

4.  Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis.

Authors:  S Chen; S M Akbar; K Tanimoto; T Ninomiya; H Iuchi; K Michitaka; N Horiike; M Onji
Journal:  Cancer Lett       Date:  2000-01-01       Impact factor: 8.679

Review 5.  Innate and adaptive lymphoid cells in the human liver.

Authors:  D G Doherty; C O'Farrelly
Journal:  Immunol Rev       Date:  2000-04       Impact factor: 12.988

Review 6.  Cancer immunoediting from immune surveillance to immune escape.

Authors:  Ryungsa Kim; Manabu Emi; Kazuaki Tanabe
Journal:  Immunology       Date:  2007-03-26       Impact factor: 7.397

7.  Human CD4(+) T cells recognize an epitope within alpha-fetoprotein sequence and develop into TGF-beta-producing CD4(+) T cells.

Authors:  Akeel Alisa; Sandra Boswell; Ansar A Pathan; Lakshmana Ayaru; Roger Williams; Shahriar Behboudi
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.

Authors:  Nadia Guerra; Ying Xim Tan; Nathalie T Joncker; Augustine Choy; Fermin Gallardo; Na Xiong; Susan Knoblaugh; Dragana Cado; Norman M Greenberg; Norman R Greenberg; David H Raulet
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

10.  Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma.

Authors:  Keisuke Kohga; Tetsuo Takehara; Tomohide Tatsumi; Kazuyoshi Ohkawa; Takuya Miyagi; Naoki Hiramatsu; Tatsuya Kanto; Tsutomu Kasugai; Kazuhiro Katayama; Michio Kato; Norio Hayashi
Journal:  Cancer Sci       Date:  2008-08       Impact factor: 6.716

View more
  20 in total

1.  Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.

Authors:  Ryoko Yamada; Naoki Hiramatsu; Tsugiko Oze; Naoki Morishita; Naoki Harada; Takayuki Yakushijin; Sadaharu Iio; Yoshinori Doi; Akira Yamada; Akira Kaneko; Hideki Hagiwara; Eiji Mita; Masahide Oshita; Toshifumi Itoh; Hiroyuki Fukui; Taizo Hijioka; Kazuhiro Katayama; Shinji Tamura; Harumasa Yoshihara; Yasuharu Imai; Michio Kato; Takuya Miyagi; Yuichi Yoshida; Tomohide Tatsumi; Akinori Kasahara; Toshimitsu Hamasaki; Norio Hayashi; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2014-11-11       Impact factor: 7.527

2.  Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells.

Authors:  Angela D Pardee; Jian Shi; Lisa H Butterfield
Journal:  J Immunol       Date:  2014-10-29       Impact factor: 5.422

3.  Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma.

Authors:  Angela D Pardee; Hiroshi Yano; Aliyah M Weinstein; Aaron A K Ponce; Alexander D Ethridge; Daniel P Normolle; Lazar Vujanovic; Gerald J Mizejewski; Simon C Watkins; Lisa H Butterfield
Journal:  J Immunother Cancer       Date:  2015-07-21       Impact factor: 13.751

4.  Characterization of alpha-fetoprotein effects on dendritic cell and its function as effector immune response activator.

Authors:  Jeremiah Suryatenggara; Heri Wibowo; Wahyuni Lukita Atmodjo; George Mathew
Journal:  J Hepatocell Carcinoma       Date:  2017-11-28

Review 5.  Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity.

Authors:  Xiaoping Wang; Qiaoxia Wang
Journal:  Can J Gastroenterol Hepatol       Date:  2018-04-01

6.  Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort.

Authors:  Yuk Ting Ma; Pankaj Punia; Mehran Afshar; Peter Fletcher; Antonio D Bardoli
Journal:  Oncotarget       Date:  2018-03-30

7.  Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients.

Authors:  Long-Shan Ji; Qiu-Tian Gao; Ruo-Wen Guo; Xin Zhang; Zhen-Hua Zhou; Zhuo Yu; Xiao-Jun Zhu; Ya-Ting Gao; Xue-Hua Sun; Yue-Qiu Gao; Man Li
Journal:  J Immunol Res       Date:  2019-01-13       Impact factor: 4.818

8.  Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection.

Authors:  Yasuteru Kondo; Masashi Ninomiya; Eiji Kakazu; Osamu Kimura; Tooru Shimosegawa
Journal:  ISRN Gastroenterol       Date:  2013-01-16

9.  Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors.

Authors:  Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mroczek-Musulman; Alicia M Waters; Jennifer M Coleman; Virginia Kelly; James M Markert; G Yancey Gillespie; Gregory K Friedman; Elizabeth A Beierle
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

10.  Chromatin Binding of c-REL and p65 Is Not Limiting for Macrophage IL12B Transcription During Immediate Suppression by Ovarian Carcinoma Ascites.

Authors:  Annika Unger; Florian Finkernagel; Nathalie Hoffmann; Felix Neuhaus; Barbara Joos; Andrea Nist; Thorsten Stiewe; Alexander Visekruna; Uwe Wagner; Silke Reinartz; Sabine Müller-Brüsselbach; Rolf Müller; Till Adhikary
Journal:  Front Immunol       Date:  2018-06-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.